Imbruvica (ibrutinib) wani magani ne na canzawa wanda yake wakiltar sauyawar teku a yadda muke kula da cutar cutar sankarar lymphocytic na kullum (CLL) da sauran lalata maras amfani da B-cell. Ƙari musamman, Imbruvica canza cutar cutar sankarar rigakafi daga buckshot chemotherapy clumsiness zuwa sniper-kamar enzymatic finesse.
Menene CLL?
Likitan cutar sankarar lymphocytic na zamani shi ne mafi yawan tsofaffin cutar sankarar bargo a kasashen yammaci.
(Mafi yawan cututtuka na rinjaye launin fata kuma ya fadi da yawa daga cikin jama'ar Amurka, al'ummar Sahara, da kuma Asians.) Wannan cutar ta fi yawa a cikin tsofaffi da shekaru masu yawa na ganewar asali na 72.
Likimamin jini na lymphocytic na yau da kullum shine ciwon daji na B na lymphocytes na B wanda ke ba da kariya ga mummunan kullun kuma ya zama wani bangare na tsarin mu na rigakafi.
Tare da CLL, damuwa da lymphocytes na Leukemic B ta tara kuma suna fitar da kwayoyin jini na al'ada a cikin kasusuwan jini, jini da lymph nodes. Tare da ciwon ƙwayoyin jini wanda jikin mu yana buƙatar jini da jini da jini, CLL zai iya haifar da iyawarmu don yaki da kamuwa da cuta da kuma haifar da anemia.
Fassarar ga mutane tare da CLL suna gudanar da gamut. Wasu mutane suna da sa'a kuma suna rayuwa a cikin shekaru da yawa tare da rashin tausayi ko ƙananan cututtukan da ba su buƙatar magani. Wasu, duk da haka, suna fuskantar wata hanya mai hatsarin gaske wadda ke da wuyar maganin cutar shan-jiji.
Misali bayyanar cututtuka a cikin waɗanda ke fama da sauri CLL sun haɗa da wadannan:
- gajiya
- asarar nauyi
- zazzabi
- dare sha
- ƙaddamar da ƙwayoyin lymph nodes
- ƙarar girma ko kuma hanta yana taimakawa wajen jin daɗi (farkon jin dadi)
- ciwon kamuwa da cuta
A shekara ta 2015, Cibiyar Cancer na Cibiyar Cancer ta kiyasta cewa daga cikin laifuka 14620 na CLL da aka gano, akwai mutuwar 4650.
Menene Musamman game da Imbruvica
Har zuwa kwanan nan, magani na CLL an iyakance shi ne zuwa chemotherapy hade tare da immunotherapy ko chemoimmunotherapy.
Kodayake cutar chemotherapy ta kanta tana da matukar damuwa ga wasu daga cikin wadanda ke tare da CLL, ƙarin da ake samu na rituximab, magani na rigakafin rigakafi, zai iya taimakawa wajen farfado da rayuwa ta hanyar haifar da gafara. Bugu da ƙari, rituximab ta sa ido ga antigen na CD20 akan ƙwayoyin B. Abin takaici, wasu takunkumi na mutane (wadanda suke tare da maye gurbin [17p] / TP53 ko sharewa a cikin chromosome 17) ba su da talauci ga chemoimmunotherapy.
Chemotherapy don CLL ya shafi gwamnatin iyaye (injection) na daban-daban jamiái don kashewa ba kawai hanzarin raba rayukan layin ba amma har ma yakan rarraba layin salula, ma. Wannan shirin ya nuna dalilin da ya sa mutane a kan chemo suna fama da mummunan cututtuka ciki har da hasara gashi, damuwa na gastrointestinal, kuma, a cikin yanayin CLL, ko da mawuyacin hali ko sakamako mai zafi.
Ganin cewa chemo ya yarda da daidaitattun shinge na sarkar gani, Imbruvica kamar likitan likita ne kuma daidai a cikin tsarin. Musamman, Imbruvica ya fitar da wani enzyme da ake kira Bruton ta tyrosine kinase (Btk) ya bambanta ga sutura ko leukemic B. Ta hanyar ba da izini ga Btk, Imbruvica yana sanya ƙuƙwalwar biri a cikin hanya mai karfin B ta hanyar ƙwaƙwalwar lokaci ta haka yana hana ƙwayar tantanin halitta, haɓakawa, da kuma tsira daga cikin kwayoyin B mai kyau.
Abin sha'awa shine, masu bincike sun nuna cewa Imbruvica na iya aiki ta wata hanyar da ta hade wanda ya hada da yada kwayar halitta wadda kwayoyin leukemic ke bunkasa. Musamman, kuma kamar yadda aka kwatanta a mujallar Nature Biotechnology , Imbruvica na iya "toshe mai karbaccen mai karba da kuma alamar integrin ta hanyar hana BTK, sabili da haka ƙaurawar ƙwayoyin cuta da kuma adhesion a cikin kwayoyin stromal a cikin kumburi na lymph. sun mutu a can, ba su da magungunan tallafin da aka ba da kumburi na lymph. "
Bayan CLL, Imbruvica kuma yana taimakawa da wasu sauran lalatawar B-cell.
Saboda haka, ban da CLL, FDA ta bayar da miyagun ƙwayoyi da sauri ko kuma tabbatar da mahimmanci ga magungunan Macroglobulinmia da kuma cell lymphoma na mantle. Babu wani miyagun ƙwayoyi da ya karbi wannan sanarwa da yawa!
Idan kai ko ƙaunatacce ke shan wahala daga CLL ko wani lalatacciyar B-cell, Ibutru na farko shine abin da za a yi farin ciki. Dangane da mummunar jini, ba za a iya kwatanta nasarar da Imbruvica ya yi ba tare da rituximab. Bugu da ƙari kuma, Imbruvica ba kawai yafi tasiri fiye da rituximab a matsayin monotherapy amma har da yin amfani da maganganu da amfani tare da cututtuka da sake koma baya.
Sources:
Mataki mai suna "Imbruvica-na gaba da miyagun ƙwayoyi a ciwon B-cell-yarda da FDA" da Malini Guha ya wallafa a cikin Nature Biotechnology a shekarar 2014.
Mataki na farko mai suna "Ibrutinib (Imbruvica): Wani Litattafan Mahimmancin Maganin Ciwon Lurarre na Likita" wanda S Parmar da mawallafin marubuta suka buga a P & T a shekara ta 2014.